

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
Center for Medicare
7500 Security Boulevard
Baltimore, Maryland 21244-1850



MEDICARE DRUG BENEFIT AND C&D DATA GROUP

DATE: August 30, 2013

TO: Medicare-Medicaid Plans

FROM: Cynthia G. Tudor, Ph.D.
Director, Medicare Drug Benefit and C&D Data Group

SUBJECT: Request for Comments on Medicare-Medicaid Plan (MMP) Tier Models for CY 2015

The purpose of this memorandum is to solicit feedback from Medicare-Medicaid Plans (MMPs) on potential changes or enhancements to MMP-specific formulary tier models for Contract Year (CY) 2015.

For CY 2014, MMPs were provided new MMP-specific tier models based on our experience with the CY 2013 integrated formulary submissions. Under the CY 2014 tier models, MMPs have the option of selecting a formulary tier model consisting of 2 to 6 tiers. Part D drugs may only be included on the first two tiers regardless of the tier model selected. For formulary models with 3 to 6 tiers, non-Part D drugs/OTCs may be included only on tiers 3 to 6, with the first two tiers being reserved for Part D drugs only. For 2-tier formulary designs, both tiers must include Part D drugs and at least one tier must contain both Part D and non-Part D drugs. A 2-tier formulary model cannot include a tier with only non-Part D drugs. The CY 2014 MMP tier models are attached to this email for reference purposes.

Some MMPs expressed concern that the availability of only 2 tiers for Part D drugs in the CY 2014 limited their ability to create separate preferred Part D brand and/or generic drug or vaccine-only tiers. We are therefore providing MMPs with an opportunity to provide us with feedback about the CY 2014 tier models and suggestions for changes or enhancements to the CY 2015 models.

MMPs should submit any comments to CMS at both MMCOCapsModel@cms.hhs.gov and PartDBenefits@cms.hhs.gov by September 13, 2013.